DrugCite
Search

RITONAVIR SOFT GELATIN CAPSULES

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Ritonavir Soft Gelatin Capsules Adverse Events Reported to the FDA Over Time

How are Ritonavir Soft Gelatin Capsules adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Ritonavir Soft Gelatin Capsules, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Ritonavir Soft Gelatin Capsules is flagged as the suspect drug causing the adverse event.

Most Common Ritonavir Soft Gelatin Capsules Adverse Events Reported to the FDA

What are the most common Ritonavir Soft Gelatin Capsules adverse events reported to the FDA?

Death
255 (4.64%)
Diarrhoea
82 (1.49%)
Pyrexia
79 (1.44%)
Drug Exposure During Pregnancy
77 (1.4%)
Vomiting
76 (1.38%)
Pneumonia
66 (1.2%)
Nausea
61 (1.11%)
Sepsis
57 (1.04%)
Abortion Spontaneous
50 (.91%)
Cerebral Haemorrhage
47 (.86%)
Headache
47 (.86%)
Show More Show More
Immune Reconstitution Syndrome
46 (.84%)
Anaemia
43 (.78%)
Metabolic Acidosis
43 (.78%)
Renal Failure
43 (.78%)
Alanine Aminotransferase Increased
41 (.75%)
Myocardial Infarction
40 (.73%)
Chest Pain
39 (.71%)
Hyperbilirubinaemia
38 (.69%)
Pancytopenia
37 (.67%)
Aspartate Aminotransferase Increase...
36 (.66%)
Weight Decreased
36 (.66%)
Dyspnoea
34 (.62%)
Renal Failure Acute
34 (.62%)
Asthenia
33 (.6%)
Convulsion
33 (.6%)
General Physical Health Deteriorati...
33 (.6%)
Liver Function Test Abnormal
33 (.6%)
Haemorrhage Intracranial
30 (.55%)
Premature Baby
29 (.53%)
Ascites
27 (.49%)
Confusional State
27 (.49%)
Dehydration
27 (.49%)
Upper Gastrointestinal Haemorrhage
24 (.44%)
Cardiac Failure
23 (.42%)
Cardiac Failure Congestive
23 (.42%)
Drug Ineffective
23 (.42%)
Hepatitis
23 (.42%)
Hiv Infection
23 (.42%)
Hypertension
23 (.42%)
Cerebrovascular Accident
22 (.4%)
Encephalopathy
22 (.4%)
Cytolytic Hepatitis
20 (.36%)
Drug Resistance
20 (.36%)
Thrombocytopenia
20 (.36%)
Drug Interaction
19 (.35%)
Fatigue
19 (.35%)
Portal Hypertension
19 (.35%)
Vision Blurred
19 (.35%)
Back Pain
18 (.33%)
Condition Aggravated
18 (.33%)
Hypotension
18 (.33%)
Osteonecrosis
18 (.33%)
Rash
18 (.33%)
Transaminases Increased
18 (.33%)
Multi-organ Failure
17 (.31%)
Pulmonary Embolism
17 (.31%)
Respiratory Failure
17 (.31%)
Abortion Induced
16 (.29%)
Brain Oedema
16 (.29%)
Cardio-respiratory Arrest
16 (.29%)
Cytomegalovirus Infection
16 (.29%)
Hypoaesthesia Facial
16 (.29%)
Pancreatitis
16 (.29%)
Respiratory Distress
16 (.29%)
Abdominal Pain
15 (.27%)
Atrioventricular Block First Degree
15 (.27%)
Cardiac Arrest
15 (.27%)
Gastroenteritis Cryptosporidial
15 (.27%)
Haemoptysis
15 (.27%)
Mycobacterium Avium Complex Infecti...
15 (.27%)
Oesophageal Candidiasis
15 (.27%)
Syncope
15 (.27%)
Blood Creatinine Increased
14 (.25%)
Coma
14 (.25%)
Depression
14 (.25%)
Dysphagia
14 (.25%)
Jaundice
14 (.25%)
Pneumocystis Jiroveci Pneumonia
14 (.25%)
Renal Impairment
14 (.25%)
Acquired Immunodeficiency Syndrome
13 (.24%)
Cardiac Murmur
13 (.24%)
Disease Progression
13 (.24%)
Hepatic Cirrhosis
13 (.24%)
Meningeal Disorder
13 (.24%)
Oedema Peripheral
13 (.24%)
Pregnancy
13 (.24%)
Progressive Multifocal Leukoencepha...
13 (.24%)
Urinary Tract Infection
13 (.24%)
Cachexia
12 (.22%)
Caesarean Section
12 (.22%)
Dialysis
12 (.22%)
Fall
12 (.22%)
Heart Rate Increased
12 (.22%)
Hepatitis Acute
12 (.22%)
Myalgia
12 (.22%)
Pericarditis
12 (.22%)
Pre-eclampsia
12 (.22%)
Sinus Bradycardia
12 (.22%)
Blood Bilirubin Increased
11 (.2%)
Cardiac Tamponade
11 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Ritonavir Soft Gelatin Capsules, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ritonavir Soft Gelatin Capsules is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Ritonavir Soft Gelatin Capsules

What are the most common Ritonavir Soft Gelatin Capsules adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Ritonavir Soft Gelatin Capsules, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Ritonavir Soft Gelatin Capsules is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Ritonavir Soft Gelatin Capsules According to Those Reporting Adverse Events

Why are people taking Ritonavir Soft Gelatin Capsules, according to those reporting adverse events to the FDA?

Hiv Infection
1372
Drug Use For Unknown Indication
102
Drug Exposure During Pregnancy
89
Antiretroviral Therapy
17
Acquired Immunodeficiency Syndrome
16
Systemic Antiviral Treatment
14
Show More Show More
Hiv Test Positive
12
End Stage Aids
6
Antiviral Prophylaxis
5
Prophylaxis
5
Lipodystrophy Acquired
3
Hepatitis C Virus Test
3
Prophylaxis Against Hiv Infection
3
Multiple-drug Resistance
3
Retroviral Infection
2
Paternal Drugs Affecting Foetus
2
Hepatic Cirrhosis
2
Drug Resistance
2
Product Used For Unknown Indication
1

Ritonavir Soft Gelatin Capsules Case Reports

What Ritonavir Soft Gelatin Capsules safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Ritonavir Soft Gelatin Capsules. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Ritonavir Soft Gelatin Capsules.